title: [Expression of cardiotrophin-1 and effects of irbesartan in adriamycin induced cardiomyopathy in rats].
abstract: OBJECTIVE
  To investigate cardiotrophin-1(CT-1) expression in the ventricle and the effects of angiotensin II type I receptor antagonist (AT(1)RA) irbesartan on the ventricular remodeling in adriamycin myocardiopathy.
  
  
  METHODS
  Thirty male SD rats were randomized into 2 groups: a control group (n=10) and a model group (n=20). The model group was administered adriamycin and 18 rats survived. And theses rats were randomized again into 2 groups. One was treated with irbesartan [50 mg/(kg x d), with stomach-tube], and the other received equal saline, so did the control group. After 12 weeks, the protein level of CT-1 was detected by immunohistochemistry.
  
  
  RESULTS
  Ventricular CT-1 in the model control group and the treatment group was higher than that in the control group and the correlation analysis showed that ventricular CT-1 of the model control group was positively correlated with the left ventricular weight index, and CT-1 of the treatment group was lower than that of the model control group.
  
  
  CONCLUSIONS
  CT-1 was assumed to take part in the ventricular remodeling. The mechanism of irbesartan on the ventricular remodeling may be related to the downregulation of CT-1 expression.
authors.affiliation: Department of Gerontology, Xiangya Hospital, Central South University, Changsha 410008, China.
authors.forename: Han-Ping
authors.initials: HP
authors.lastname: Zhuang
authors.forename: Jia-Mei
authors.initials: JM
authors.lastname: Yao
authors.forename: Ying
authors.initials: Y
authors.lastname: Chen
authors.forename: Chuan-Chang
authors.initials: CC
authors.lastname: Li
mesh_terms: D047228:Angiotensin II Type 1 Receptor Blockers / Q000494:pharmacology; D000818:Animals; D001713:Biphenyl Compounds / Q000494:pharmacology*; D009202:Cardiomyopathies / Q000139:chemically induced / Q000378:metabolism*; D016207:Cytokines / Q000378:metabolism*; D004317:Doxorubicin / Q000009:adverse effects; D000077405:Irbesartan; D008297:Male; D032383:Myocytes, Cardiac / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013777:Tetrazoles / Q000494:pharmacology*; D020257:Ventricular Remodeling / Q000187:drug effects*
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D001713:Biphenyl Compounds; D016207:Cytokines; D013777:Tetrazoles; D004317:Doxorubicin; C092073:cardiotrophin 1; D000077405:Irbesartan